Char syndrome: Difference between revisions

From WikiMD's Wellness Encyclopedia

Deepika vegiraju (talk | contribs)
No edit summary
Tag: visualeditor-wikitext
 
CSV import
 
Line 1: Line 1:
{{SI}}
{{Infobox medical condition
| name            = Char syndrome
| image          = [[File:Autosomal_dominant_-_en.svg|200px]]
| caption        = Char syndrome is inherited in an [[autosomal dominant]] pattern.
| synonyms        = Patent ductus arteriosus with facial dysmorphism and hand anomalies
| pronounce      =
| specialty      = [[Medical genetics]]
| symptoms        = [[Facial dysmorphism]], [[patent ductus arteriosus]], [[hand anomalies]]
| onset          = Congenital
| duration        = Lifelong
| causes          = Mutations in the [[TFAP2B]] gene
| risks          = Family history of the condition
| diagnosis      = [[Genetic testing]], clinical evaluation
| differential    = Other syndromes with similar features
| prevention      = Genetic counseling
| treatment      = Symptomatic treatment, surgical correction of heart defects
| medication      =
| prognosis      = Variable, depending on severity of symptoms
| frequency      = Rare
}}
'''Other Names: '''
'''Other Names: '''
CHAR; Patent ductus arteriosus with facial dysmorphism and abnormal fifth digits
CHAR; Patent ductus arteriosus with facial dysmorphism and abnormal fifth digits
Char syndrome is a condition that affects the development of the face, heart, and limbs.  
Char syndrome is a condition that affects the development of the face, heart, and limbs.  
It is characterized by a combination of three major features: a distinctive facial appearance, a heart defect called [[patent ductus arteriosus]], and hand abnormalities.
It is characterized by a combination of three major features: a distinctive facial appearance, a heart defect called [[patent ductus arteriosus]], and hand abnormalities.
== '''Genetics''' ==
== '''Genetics''' ==
[[File:Autosomal dominant - en.svg|thumb|right|[[Autosomal dominant]] pattern, a 50/50 chance.]]
Char syndrome is caused by [[mutations]] in the [[TFAP2B]] [[gene]] and is [[inherited]] in an [[autosomal dominant]] fashion.  
Char syndrome is caused by [[mutations]] in the [[TFAP2B]] [[gene]] and is [[inherited]] in an [[autosomal dominant]] fashion.  
During [[embryo]] development, [[TFAP2B]] regulates the production of the [[protein]] [[AP-]], a [[transcription]] factor that is active in the neural crest and helps regulate genes that control [[cell division]] and [[apoptosis]].
During [[embryo]] development, [[TFAP2B]] regulates the production of the [[protein]] [[AP-2β]], a [[transcription]] factor that is active in the neural crest and helps regulate genes that control [[cell division]] and [[apoptosis]].
There are at least 10 [[mutations]] of this gene that has been identified in people presenting Char syndrome,
There are at least 10 [[mutations]] of this gene that has been identified in people presenting Char syndrome,
which alters specific regions of the gene preventing production of the transcription factor and disrupting normal development of embryo structures.
which alters specific regions of the gene preventing production of the transcription factor and disrupting normal development of embryo structures.
== '''Symptoms''' ==
== '''Symptoms''' ==
For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed.  
For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed.  
Line 27: Line 43:
* Thick vermilion borde(Full lips)
* Thick vermilion borde(Full lips)
* Triangular mouth(Triangular shaped mouth)
* Triangular mouth(Triangular shaped mouth)
30%-79% of people have these symptoms
30%-79% of people have these symptoms
* Clinodactyly of the 5th finger(Permanent curving of the pinkie finger)
* Clinodactyly of the 5th finger(Permanent curving of the pinkie finger)
* Mesoaxial hand polydactyly
* Mesoaxial hand polydactyly
* Short middle phalanx of the 5th finger(Short middle bone of the little finger)
* Short middle phalanx of the 5th finger(Short middle bone of the little finger)
5%-29% of people have these symptoms
5%-29% of people have these symptoms
* Global developmental delay
* Global developmental delay
Line 47: Line 61:
* Toe syndactyly(Fused toes)
* Toe syndactyly(Fused toes)
* Ventricular septal defect(Hole in heart wall separating two lower heart chambers)
* Ventricular septal defect(Hole in heart wall separating two lower heart chambers)
== '''Diagnosis''' ==
== '''Diagnosis''' ==
Making a diagnosis for a genetic or rare disease can often be challenging.  
Making a diagnosis for a genetic or rare disease can often be challenging.  
The [[Genetic Testing Registry]] (GTR) provides information about the genetic tests for this condition.  
The [[Genetic Testing Registry]] (GTR) provides information about the genetic tests for this condition.  
The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.
The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.
== '''Treatment''' ==
== '''Treatment''' ==
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.
'''[[Ibuprofen lysine]]''' (Brand name: NeoProfen®)For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g,
'''[[Ibuprofen lysine]]''' (Brand name: NeoProfen®)For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g,
  who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc)
  who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc)
[[Category:Congenital disorders]]
[[Category:Congenital disorders]]
{{stub}}
{{stub}}
{{rarediseases}}
{{rarediseases}}

Latest revision as of 23:51, 5 April 2025

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC

Char syndrome
Synonyms Patent ductus arteriosus with facial dysmorphism and hand anomalies
Pronounce
Specialty Medical genetics
Symptoms Facial dysmorphism, patent ductus arteriosus, hand anomalies
Complications N/A
Onset Congenital
Duration Lifelong
Types N/A
Causes Mutations in the TFAP2B gene
Risks Family history of the condition
Diagnosis Genetic testing, clinical evaluation
Differential diagnosis Other syndromes with similar features
Prevention Genetic counseling
Treatment Symptomatic treatment, surgical correction of heart defects
Medication
Prognosis Variable, depending on severity of symptoms
Frequency Rare
Deaths N/A


Other Names: CHAR; Patent ductus arteriosus with facial dysmorphism and abnormal fifth digits Char syndrome is a condition that affects the development of the face, heart, and limbs. It is characterized by a combination of three major features: a distinctive facial appearance, a heart defect called patent ductus arteriosus, and hand abnormalities.

Genetics[edit]

Char syndrome is caused by mutations in the TFAP2B gene and is inherited in an autosomal dominant fashion. During embryo development, TFAP2B regulates the production of the protein AP-2β, a transcription factor that is active in the neural crest and helps regulate genes that control cell division and apoptosis. There are at least 10 mutations of this gene that has been identified in people presenting Char syndrome, which alters specific regions of the gene preventing production of the transcription factor and disrupting normal development of embryo structures.

Symptoms[edit]

For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. 80%-99% of people have these symptoms

  • Depressed nasal bridge(Depressed bridge of nose)
  • Depressed nasal ridge(Flat nose)
  • Downslanted palpebral fissures(Downward slanting of the opening between the eyelids)
  • Everted lower lip vermilion(Drooping lower lip)
  • Hypertelorism(Wide-set eyes)
  • Malar flattening(Zygomatic flattening)
  • Patent ductus arteriosus
  • Ptosis(Drooping upper eyelid)
  • Short philtrum
  • Thick vermilion borde(Full lips)
  • Triangular mouth(Triangular shaped mouth)

30%-79% of people have these symptoms

  • Clinodactyly of the 5th finger(Permanent curving of the pinkie finger)
  • Mesoaxial hand polydactyly
  • Short middle phalanx of the 5th finger(Short middle bone of the little finger)

5%-29% of people have these symptoms

  • Global developmental delay
  • Hearing impairment(Deafness)
  • Mesoaxial foot polydactyly(Central polydactyly of feet)
  • Myopia(Close sighted)
  • No permanent dentition(Absence of adult teeth)
  • Persistence of primary teeth(Delayed loss of baby teeth)
  • Prominent occiput(Prominent back of the skull)
  • Sleep disturbance(Difficulty sleeping)
  • Strabismus(Cross-eyed)
  • Supernumerary nipple(Accessory nipple)
  • Symphalangism of the 5th finger(Fused little finger bones)
  • Toe syndactyly(Fused toes)
  • Ventricular septal defect(Hole in heart wall separating two lower heart chambers)

Diagnosis[edit]

Making a diagnosis for a genetic or rare disease can often be challenging. The Genetic Testing Registry (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Treatment[edit]

The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. Ibuprofen lysine (Brand name: NeoProfen®)For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g,

who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc)
This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia

NIH genetic and rare disease info[edit]

Char syndrome is a rare disease.